Donald Aspenson
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1225008550
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $136,411 of the $153,303 with a category attached, or 89.0%. 31 manufacturers reported payments, led by Novo Nordisk at 35.8% of the total. Reporting peaked in 2019 at $104,580 and has fallen 86.4% since, to $14,197 in 2022. Among endocrinology, diabetes & metabolism clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $439.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$55K
- Merck$37K
- Amgen$24K
- Boehringer Ingelheim$14K
- Lilly USA, LLC$14K
- AstraZeneca$6K
- plus $3K from 25 others
What the payments were for
- Consulting fees$2,9252%
- Speaking & faculty fees$136,41189%
- Travel & lodging$8,0585%
- Food & beverage$5,8844%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 81 | $54,944 |
| Merck | 58 | $36,936 |
| Amgen | 37 | $24,129 |
| Boehringer Ingelheim | 39 | $14,409 |
| Lilly USA, LLC | 48 | $13,747 |
| AstraZeneca | 24 | $5,693 |
| Johnson & Johnson | 10 | $2,488 |
| Abbott | 4 | $221 |
| Antares Pharma, Inc. | 6 | $86 |
| Regeneron Healthcare Solutions, Inc. | 5 | $78 |
| Currax Pharmaceuticals LLC | 5 | $72 |
| Medtronic | 3 | $52 |
| Endo Pharmaceuticals Inc. | 3 | $47 |
| Corcept Therapeutics | 2 | $35 |
| Novartis | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $32 |
| AbbVie | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Sandoz | 2 | $26 |
| Dexcom, Inc. | 2 | $26 |
| Gilead | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 2 | $23 |
| Valeritas, Inc. | 1 | $22 |
| Mannkind Corporation | 1 | $21 |
| Nalpropion Pharmaceuticals LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Vistapharm, Inc. | 1 | $12 |
| Siemens Medical Solutions USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$153,303 in reported general payments places this provider in the 95th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Other endocrinology, diabetes & metabolism in Tulsa
- Cristin BrunsTulsa$159K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Elie AbedTulsa$10K
- Vishnu Priya PulipatiTulsa$8K
- Maria VargasTulsa$7K
- Christian HansonTulsa$4K
- Miguel Jara PalaciosTulsa$4K
- Deepa PhilipTulsa$4K
- Alekya PolojuTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.